The wire › SEC Form 8-K
enGene Therapeutics Inc. ENGN
Filed with the SEC on Jun 15, 2026. Reported event date Jun 13, 2026.
- Business address
- Saint-laurent
- State
- Outside the U.S. or not given
- Incorporated in
- Outside the U.S. or not given
- Industry
- Manufacturing (SIC 2836)
- SEC CIK
- 1980845
- Accession number
- 0001193125-26-270384
Items reported in this filing
- Item 2.02 Results of Operations and Financial Condition
- Item 2.05 Costs Associated with Exit or Disposal Activities
The company reported a restructuring: it committed to exit or dispose of part of its business (for example closing some sites, ending a product line or cutting staff) and expects material costs, under Form 8-K Item 2.05. It does not mean the company is closing; healthy, profitable companies file it too, often alongside an earnings release.
- Item 5.02 Departure or Appointment of Directors or Officers; Compensatory Arrangements
- Item 7.01 Regulation FD Disclosure
- Item 8.01 Other Events
- Item 9.01 Financial Statements and Exhibits
Other entries on the wire for this company
Wire Pass $1.95/month or $19.50/year lets you watch up to 100 companies like this one. Free during preview See pricing